GlassScriptPhysician profile
Brooke Shannon
NPI 1740756261
$3,075.80
in general payments reported to CMS, 2019-2025
34 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,034 · 2022: $357 · 2023: $548 · 2024: $681 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,684.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $652.49 | 2021-2025 | |
| Pfizer INC. | $208.93 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $198.24 | 2021-2024 | Trintellix |
| Lilly USA, LLC | $191.47 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $180.80 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $175.13 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $167.21 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $163.03 | 2021-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Amgen INC. | $153.48 | 2021-2025 | Evenity, Prolia, Repatha |
| Astellas Pharma US INC | $119.89 | 2021-2024 | Veozah |
| Bridgebio Pharma, INC. | $105.29 | 2025 | Attruby |
| Novartis Pharmaceuticals Corporation | $102.31 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $63.99 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $59.42 | 2021 | |
| Exact Sciences Corporation | $55.78 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sage Therapeutics, LLC | $53.95 | 2024-2025 | Zurzuvae |
| Dexcom, INC. | $52.51 | 2024 | Dexcom G6 Transmitter |
| Novo Nordisk INC | $43.45 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $37.28 | 2021 | |
| Sanofi Pasteur INC. | $29.87 | 2023 | |
| Lundbeck LLC | $27.60 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $21.46 | 2025 | Zoryve |
| Heartflow, INC. | $19.97 | 2025 | |
| Sanofi-Aventis U.S. LLC | $19.73 | 2021 | |
| Organon LLC | $19.44 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $19.06 | 2025 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $17.92 | 2022 | |
| Phathom Pharmaceuticals, INC. | $17.33 | 2024 | Voquezna |
| Medtronic, INC. | $17.20 | 2025 | Minimed 780g |
| Alkermes, INC. | $16.80 | 2025 | Vivitrol |
| Esperion Therapeutics, INC. | $16.43 | 2021 | |
| Inspire Medical Systems, INC. | $16.12 | 2025 | Inspire |
| Otsuka America Pharmaceutical, INC. | $16.11 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $16.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Shannon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.